Cargando…

Myeloid-Derived Suppressor Cells in Prostate Cancer: Present Knowledge and Future Perspectives

Several lines of research are being investigated to better understand mechanisms implicated in response or resistance to immune checkpoint blockade in prostate cancer (PCa). Myeloid-derived suppressor cells (MDSCs) have emerged as a major mediator of immunosuppression in the tumor microenvironment t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koinis, Filippos, Xagara, Anastasia, Chantzara, Evangelia, Leontopoulou, Vassiliki, Aidarinis, Chrissovalantis, Kotsakis, Athanasios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750906/ https://www.ncbi.nlm.nih.gov/pubmed/35011582 http://dx.doi.org/10.3390/cells11010020

Ejemplares similares

Emerging Role of YAP and the Hippo Pathway in Prostate Cancer
por: Koinis, Filippos, et al.
Publicado: (2022)

Prognostic Role of Circulating Tumor Cells in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel: A Prospective Biomarker Study
por: Koinis, Filippos, et al.
Publicado: (2023)

Immune Checkpoint and EMT-Related Molecules in Circulating Tumor Cells (CTCs) from Triple Negative Breast Cancer Patients and Their Clinical Impact
por: Vardas, Vasileios, et al.
Publicado: (2023)

Phenotypic Characterization of Circulating Tumor Cells Isolated from Non-Small and Small Cell Lung Cancer Patients
por: Roumeliotou, Argyro, et al.
Publicado: (2022)

A Circulating Subpopulation of Monocytic Myeloid-Derived Suppressor Cells as an Independent Prognostic/Predictive Factor in Untreated Non-Small Lung Cancer Patients
por: Vetsika, Eleni-Kyriaki, et al.
Publicado: (2014)

Myeloid-Derived Suppressor Cells: Major Figures that Shape the Immunosuppressive and Angiogenic Network in Cancer
por: Vetsika, Eleni-Kyriaki, et al.
Publicado: (2019)

Criteria for the Transition to Adulthood, Developmental Features of Emerging Adulthood, and Views of the Future Among Greek Studying Youth
por: Galanaki, Evangelia, et al.
Publicado: (2017)

Prognostic value of circulating regulatory T cell subsets in untreated non-small cell lung cancer patients
por: Kotsakis, Athanasios, et al.
Publicado: (2016)

CD8(+) PD-1(+) T-cells and PD-L1(+) circulating tumor cells in chemotherapy-naïve non-small cell lung cancer: towards their clinical relevance?
por: Kotsakis, Athanasios, et al.
Publicado: (2019)

Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small cell lung cancer
por: Messaritakis, Ippokratis, et al.
Publicado: (2017)

Functional Analysis of Viable Circulating Tumor Cells from Triple-Negative Breast Cancer Patients Using TetherChip Technology
por: Vardas, Vasileios, et al.
Publicado: (2023)

Pediatric Acute Myeloid Leukemia—Past, Present, and Future
por: Reinhardt, Dirk, et al.
Publicado: (2022)

Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer
por: Kallergi, Galatea, et al.
Publicado: (2018)

Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the Hellenic Oncology Research Group
por: Katsaounis, Panagiotis, et al.
Publicado: (2018)

Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives
por: Lu, Li-Chun, et al.
Publicado: (2019)

Incidence and Risk Factors for Blood Stream Infection in Mechanically Ventilated COVID-19 Patients
por: Mantzarlis, Konstantinos, et al.
Publicado: (2022)

The Role of Myeloid-Derived Suppressor Cells (MDSCs) in Graft-versus-Host Disease (GVHD)
por: Demosthenous, Christos, et al.
Publicado: (2021)

Dynamic changes of phenotypically different circulating tumor cells sub-populations in patients with recurrent/refractory small cell lung cancer treated with pazopanib
por: Messaritakis, Ippokratis, et al.
Publicado: (2018)

Targeting myeloid-derived suppressor cells in tumor immunotherapy: Current, future and beyond
por: Zhao, Yang, et al.
Publicado: (2023)

The Connection Between Minor H Antigens and Neoantigens and the Missing Link in Their Prediction
por: Mutis, Tuna, et al.
Publicado: (2020)

Analytical and Structural Tools of Lipid Hydroperoxides: Present State and Future Perspectives
por: Kontogianni, Vassiliki G., et al.
Publicado: (2022)

Autophagy in Thyroid Cancer: Present Knowledge and Future Perspectives
por: Netea-Maier, Romana T., et al.
Publicado: (2015)

Myeloid-Derived Suppressor Cells as Key Players and Promising Therapy Targets in Prostate Cancer
por: Siemińska, Izabela, et al.
Publicado: (2022)

Myeloid Derived Suppressor Cells in Chronic Myeloid Leukemia
por: Giallongo, Cesarina, et al.
Publicado: (2015)

Targeting β-catenin in acute myeloid leukaemia: past, present, and future perspectives
por: Wagstaff, Megan, et al.
Publicado: (2022)

Analysis of the circulating myeloid‐derived suppressor cells during androgen deprivation therapy for prostate cancer
por: Kohada, Yuki, et al.
Publicado: (2021)

Aftermath of the COVID-19 Pandemic: Resilience and Mental Health of Emerging Adult University Students
por: Leontopoulou, Sophie
Publicado: (2023)

TTF-1- and/or CD56-positive Circulating Tumor Cells in patients with small cell lung cancer (SCLC)
por: Messaritakis, Ippokratis, et al.
Publicado: (2017)

Myeloid-Derived Suppressor Cells in Sepsis
por: Lai, Dengming, et al.
Publicado: (2014)

Myeloid-Derived Suppressor Cells in Sepsis
por: Schrijver, Irene T., et al.
Publicado: (2019)

On the origin of myeloid-derived suppressor cells
por: Millrud, Camilla Rydberg, et al.
Publicado: (2016)

Myeloid-derived suppressor cells in gliomas
por: Gieryng, Anna, et al.
Publicado: (2016)

Investigation of Clinically Significant Molecular Aberrations in Patients with Prostate Cancer: Implications for Personalized Treatment, Prognosis and Genetic Testing
por: Fountzilas, Elena, et al.
Publicado: (2023)

Kinetics of human myeloid-derived suppressor cells after blood draw
por: Grützner, Eva, et al.
Publicado: (2016)

Resistance to MET/VEGFR2 Inhibition by Cabozantinib Is Mediated by YAP/TBX5-Dependent Induction of FGFR1 in Castration-Resistant Prostate Cancer
por: Koinis, Filippos, et al.
Publicado: (2020)

Clinical Perspectives on Targeting of Myeloid Derived Suppressor Cells in the Treatment of Cancer
por: Najjar, Yana G., et al.
Publicado: (2013)

Evolution and Targeting of Myeloid Suppressor Cells in Cancer: A Translational Perspective
por: Bleve, Augusto, et al.
Publicado: (2022)

New Perspectives on Myeloid-Derived Suppressor Cells and Their Emerging Role in Haematology
por: Bizymi, Nikoleta, et al.
Publicado: (2022)

Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab
por: Santegoets, Saskia JAM, et al.
Publicado: (2014)

Myeloid Derived Suppressor Cells Are Present at High Frequency in Neonates and Suppress In Vitro T Cell Responses
por: Gervassi, Ana, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_tdfbto8gnqina014eog55j8ilg